Diabetes, Obesity & Metabolism · Nov 19, 2026
Naltrexone/Bupropion Significantly Improves Overweight‐ and Obesity‐Related Estimated Renal Hyperfiltration: A Post Hoc Pooled Analysis
By Tsoukas MA, Mavrakanas TA, Yin P et al.
Aims: In individuals with obesity, glomerular hyperfiltration compensates for the heightened metabolic demands of increased body weight. This study investigated whether extended‐release naltrexone/bupropion (NB) was associated with changes consistent with hyperfiltration reversal in adults with overweight or obesity. Materials and Methods: Post hoc, exploratory analyses were conducted in both per‐protocol subjects completing 56 weeks of treatment and the intention‐to‐treat population in Phase III studies (COR‐I and ‐II, COR‐BMOD). A mixed‐effects model investigated if NB was associated with changes in renal function consistent with presumed hyperfiltration reversal. Obesity‐related hyperfiltration was defined as creatinine clearance (CrCl) > 120 mL/min and estimated using the Salazar‐Corcoran equation. Results: A total of 4022 subjects were included in the ITT population (NB = 2749; placebo = 1273), of whom 1739 completed the 56 weeks of treatment (NB = 1100; placebo = 639). Average weight and BMI were 100.2 kg and 36.1 kg/m ² , respectively. At 56 weeks, mean weight loss was 9.0 kg in the NB group and 2.8 kg in the placebo group ( p < 0.0001). During that period, adjusted mean CrCl decreased by 8.4 mL/min in the NB group (from 125.1 to 116.7 mL/min), compared to a marginal increase of 0.1 mL/min in the placebo group (from 124.0 to 124.1 mL/min; between‐group difference in change of −8.5 mL/min; 95% CI: −9.7 to −7.4) in favour of NB. The adjusted percentage of subjects with CrCl values consistent with presumed obesity‐related hyperfiltration decreased significantly from 49.9% to 14.1% in the NB group and changed from 41.1% to 43.4% in the placebo group, corresponding to an absolute between‐group difference in change of −38.2 percentage points (95% CI: −55.3 to −21.0). The results were consistent in the ITT population, with adjusted rates decreasing from 35.8% to 4.0% in the NB group and from 36.7% to 33.7% in the placebo group, corresponding to an absolute between‐group difference in change of −29.7 percentage points (95% CI: −43.1 to −16.2). Conclusions: Over 56 weeks, NB was associated with a significant reduction in the proportion of subjects with presumed renal hyperfiltration compared to placebo. Trial Registration: COR‐I: NCT00532779; COR‐II: NCT00567255; COR‐BMOD: NCT00456521
doi.org/10.1111/dom.71545Open accessPubMed 43058044Interventions